[go: up one dir, main page]

MX2009006359A - Derivados de aril sulfamida y metodos para su uso. - Google Patents

Derivados de aril sulfamida y metodos para su uso.

Info

Publication number
MX2009006359A
MX2009006359A MX2009006359A MX2009006359A MX2009006359A MX 2009006359 A MX2009006359 A MX 2009006359A MX 2009006359 A MX2009006359 A MX 2009006359A MX 2009006359 A MX2009006359 A MX 2009006359A MX 2009006359 A MX2009006359 A MX 2009006359A
Authority
MX
Mexico
Prior art keywords
disorders
methods
derivatives
sulfamide derivatives
aryl sulfamide
Prior art date
Application number
MX2009006359A
Other languages
English (en)
Inventor
Eugene John Trybulski
Douglas John Jenkins
Paige Erin Mahaney
Stephen Todd Cohn
Eugene Anthony Terefenko
Callain Younghee Kim
An Thien Vu
Puwen Zhang
Michael Anthony Marella
Richard Page Woodworth Jr
Andrew Fensome
Casey Cameron Mc Comas
Matthew L Crawley
Joel Adam Goldberg
Charles William Mann
David John O'neill
Joseph P Sabatucci
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009006359A publication Critical patent/MX2009006359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se dirige a derivados de ant sulfamida de la fórmula 1: (ver fórmula (I)) una sal farmacéuticamente aceptable, estereoisómero o tautómero de estos, que son inhibidores de recaptación de monoamina, composiciones que contienen estos derivados, y métodos para su uso para la prevención y tratamiento de afecciones, que incluyen, ínter alia, síntomas vasomotrices, disfunción sexual, trastornos gastrointestinales y trastorno genitourinario, trastornos depresivos, trastornos de comportamiento endogéno, trastornos cognitivos, neuropatía diabética, dolor, y otros enfermedades y trastornos.
MX2009006359A 2006-12-12 2007-12-12 Derivados de aril sulfamida y metodos para su uso. MX2009006359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12
PCT/US2007/025405 WO2008073459A1 (en) 2006-12-12 2007-12-12 Aryl sulfamide derivatives and methods of their use

Publications (1)

Publication Number Publication Date
MX2009006359A true MX2009006359A (es) 2009-06-26

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006359A MX2009006359A (es) 2006-12-12 2007-12-12 Derivados de aril sulfamida y metodos para su uso.

Country Status (20)

Country Link
US (4) US20080161366A1 (es)
EP (1) EP2061776A1 (es)
JP (1) JP2010512401A (es)
KR (1) KR20090087506A (es)
CN (1) CN101600701A (es)
AR (1) AR064318A1 (es)
AU (1) AU2007333593A1 (es)
BR (1) BRPI0720289A2 (es)
CA (1) CA2671844A1 (es)
CL (1) CL2007003590A1 (es)
CR (1) CR10866A (es)
EC (1) ECSP099411A (es)
MX (1) MX2009006359A (es)
NO (1) NO20092092L (es)
PE (1) PE20081395A1 (es)
RU (1) RU2009121017A (es)
SV (1) SV2009003295A (es)
TW (1) TW200843753A (es)
WO (1) WO2008073459A1 (es)
ZA (1) ZA200904109B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076502A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
US9108937B2 (en) * 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
EP2776387B1 (en) * 2011-11-07 2017-02-01 Emory University Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
WO2019243523A1 (en) * 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
HU230538B1 (hu) * 2000-08-14 2016-11-28 Ortho Mcneil Pharmaceutical, Inc. Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
KR100729242B1 (ko) * 2001-04-18 2007-06-15 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
MXPA04006344A (es) * 2001-12-28 2005-03-31 Takeda Pharmaceutical Preventivos/remedios para la perturbacion de miccion.
WO2006114706A1 (en) * 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
WO2007041258A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake

Also Published As

Publication number Publication date
NO20092092L (no) 2009-08-19
US20100029641A1 (en) 2010-02-04
EP2061776A1 (en) 2009-05-27
CL2007003590A1 (es) 2008-02-29
SV2009003295A (es) 2009-10-29
US20080194654A1 (en) 2008-08-14
ECSP099411A (es) 2009-07-31
JP2010512401A (ja) 2010-04-22
BRPI0720289A2 (pt) 2014-02-04
ZA200904109B (en) 2010-04-28
WO2008073459A1 (en) 2008-06-19
CN101600701A (zh) 2009-12-09
CR10866A (es) 2009-07-14
PE20081395A1 (es) 2008-09-17
AU2007333593A1 (en) 2008-06-19
CA2671844A1 (en) 2008-06-19
RU2009121017A (ru) 2011-01-20
US7601722B2 (en) 2009-10-13
US20080161366A1 (en) 2008-07-03
AR064318A1 (es) 2009-03-25
US20080167303A1 (en) 2008-07-10
TW200843753A (en) 2008-11-16
KR20090087506A (ko) 2009-08-17

Similar Documents

Publication Publication Date Title
MX2009006359A (es) Derivados de aril sulfamida y metodos para su uso.
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
EA201690391A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2007084841A3 (en) Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
EA201290329A1 (ru) Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2011003691A (es) Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
MY177058A (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors
MX2009003981A (es) Agentes moduladores del receptor de calcio.
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
UA105649C2 (uk) Хінолонова сполука і фармацевтична композиція
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
MX2009006360A (es) Derivados de dihidrobenzofuranilo y metodos para su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal